Previous studies have also shown therapeutic role of Smad2, that blocking Smad2 could suppress TGF-β-induced tumorigenesis, epithelial-mesenchymal transition (EMT), cell motility, and invasion [45], indicating that targeting miR-27a/Smad2 could have a great impact on developing a novel strategy for colorectal cancer therapy. The gene discussed is TGFB1; the disease is colorectal cancer.